References

• Andreazza AC, Frey BN, Erdtmann B, Salvador M, Rombaldi F, Santin A, et al. DNA damage in disorder. Psychiatry Res 2007; 153(1): 27–32.
   PubMed Web of Science ®Google Scholar
• Belmaker RH. Medical progress: bipolar disorder. N Engl J Med 2004; 351(5): 476–86.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. The utility of DALYs for public health policy and research: a reply. Bull World Health Organ 1997; 75(4): 377–81.
   Web of Science ®Google Scholar
• Carter CJ. Multiple genes and factors associated with disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: Implications for oligodendrocyte viability. Neurochem Int 2007: 50(3): 461–90.
   Web of Science ®Google Scholar
• Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003:38(2): 157–60.
   PubMed Web of Science ®Google Scholar
• Gould TD, Manji HK. The Wnt signaling pathway in disorder. Neuroscientist 2002; 8(5): 497–511.
   Web of Science ®Google Scholar
• Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004; 45(2): 104–14.
   PubMedGoogle Scholar
• Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. The course of nitric oxide and superoxide dismutase during treatment of depressive episode. J Affect Disord 2008; 107(1–3): 89–94.
   PubMed Web of Science ®Google Scholar
• Black MD, Selk DE, Hitchcock JM, Wettstein JG, Sorensen SM. On the effect of neonatal nitric oxide synthase inhibition rats: a potential neurodevelopmental model in schizophrenia. Neuropharmacology 1999; 38(9): 1299–306.
   PubMed Web of Science ®Google Scholar
• Papageorgiou C, Grapsa E, Christodoulou NG, Zerefos N, Stamatelopoulos S, Christodoulou GN. Association of serum nitric oxide levels with depressive symptoms: a study with end-stage renal failure patients. Psychother Psychosom 2001; 70(4): 216–20.
   Web of Science ®Google Scholar
• Champe PC and Harvey RA. Lippincott's illustrated reviews: Biochemistry: Lippincott Co, Philadelphia. 1987.
   Google Scholar
• Savaş HA, Herken H, Yürekli M, Uz E, Tutkun H, Zoroğlu SS, et al. Possible role of nitric oxide and adrenomedullin in affective disorder. Neuropsychobiology 2002; 45(2): 57–61.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Kehong Z, Baldessarini RJ. Long term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide 2002; 7(4): 297–300.
   Web of Science ®Google Scholar
• Varol Tas F, Guvenir T, Tas G, Cakaloz B, Ormen M. Nitric oxide levels in disruptive behavioral disorder. Neuropsychobiology 2006; 53(4): 176–80.
   PubMed Web of Science ®Google Scholar
• Hoekstra R, Fekkes D, Pepplinkhuizen L. Nitric Oxide and Neopterin in Affective Disorder. Neuropsychobiology 2006; 54(1): 75–81.
   PubMed Web of Science ®Google Scholar
• Harvey BH. Affective disorders and nitric oxide: a role in pathways to relapse and refractoriness? Hum Psychopharmacol 1996; 11: 309–19.
   Web of Science ®Google Scholar
• Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 2004; 18(3): 377–90.
   Web of Science ®Google Scholar
• Das I, Khan NS, Puri BK, Hirsch SR. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci Lett 1996; 215(3): 209–11.
   Web of Science ®Google Scholar
• Selley ML. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 2003; 24(7): 903–7.
   Web of Science ®Google Scholar
• Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord 2004; 80(2–3): 249–56.
   PubMed Web of Science ®Google Scholar
• van Amsterdam JG, Opperhuizen A. Nitric oxide and biopterin in depression and stress. Psychiatry Res 1999; 85(1): 33–8.
   Web of Science ®Google Scholar
• Demas GE, Kriegsfeld LJ, Blackshaw S, Huang P, Gammie SC, Nelson RJ, et al. Elimination of aggressive behavior in male mice lacking endothelial nitric oxide synthase. J Neurosci 1999; 19(19): 30.
   Web of Science ®Google Scholar
• Snyder SH, Ferris CD. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000; 157(11): 1738–51.
   PubMed Web of Science ®Google Scholar
• Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(7): 1677–81.
   PubMed Web of Science ®Google Scholar
• Richardson MA, Read LL, Taylor Clelland CL, Reilly MA, Chao HM, Guynn RW, et al. Evidence for a tetrahydrobiopterin deficit in schizophrenia Neuropsychobiology 2005; 52(4): 190–201.
   Google Scholar
• Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenic patients. Psychopharmacology (Berl) 2001; 158(2): 140–5.
   Google Scholar
• Herken H, Uz E, Ozyurt H, Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 2001; 52(3): 289–90.
   Web of Science ®Google Scholar
• Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-III-R Axis I Disorders (SCID-I). Washington DC: American Psychiatric Pres Inc; 1987.
   Google Scholar
• First MB, Spitzer RL, Gibbon M. Structured Clinical İnterview for DSM-IV Axis I Disorders (SCID-I) Clinical Version. Washington DC: American Psychiatric Pres Inc; 1997.
   Google Scholar
• Özer S, Demir B, Tuğal Ö, Kabakçı E, Yazıcı MK. Montgomery Åsberg Depresyon Değerlendirme Ölçeği: Değerlendiriciler Arası Güvenilirlik ve Geçerlik Çalışması. Turk Psikiyatri Derg 2001; 12(3): 185–94. (Turkish)
   Google Scholar
• Karadağ F, Oral ET, Yalçın FA, Erten E. Young Mani Derecelendirme Ölçeğinin Türkiye'de Geçerlik ve Güvenilirliği. Turk Psikiyatri Derg 2002; 13(2): 107–14. (Turkish)
   PubMedGoogle Scholar
• Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan N, Özbay H. Hamilton Depresyon Derecelendirme Ölçeği'nin Geçerliliği, Güvenilirliği ve Klinikte Kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996:4(4): 251–9. (Turkish)
   Google Scholar
• Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004; 19(2): 89–95.
   PubMed Web of Science ®Google Scholar
• Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008; 28(2): 425–33.
   Web of Science ®Google Scholar
• Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 1995; 212(2): 375–80.
   PubMed Web of Science ®Google Scholar
• Baba H, Suzuki T, Arai H, Emson PC. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 2004; 15(4): 677–80.
   PubMed Web of Science ®Google Scholar
• MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119(8): 1533–40.
   PubMed Web of Science ®Google Scholar